BE657005A - - Google Patents
Info
- Publication number
- BE657005A BE657005A BE657005A BE657005A BE657005A BE 657005 A BE657005 A BE 657005A BE 657005 A BE657005 A BE 657005A BE 657005 A BE657005 A BE 657005A BE 657005 A BE657005 A BE 657005A
- Authority
- BE
- Belgium
- Prior art keywords
- sorbitol
- vitamins
- medicaments according
- antibiotic
- intestinal
- Prior art date
Links
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims 1
- 210000005027 intestinal barrier Anatomy 0.000 claims 1
- 230000007358 intestinal barrier function Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 description 5
- 241000304886 Bacilli Species 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
<Desc/Clms Page number 1>
"Nouvelles associations médicamenteuses destinées à la reconsti- tution de la flore intestinale"
On sait l'importance que revêt après un traitement aux antibiotiques le réensemencement de la flore intestinale, toujours plus ou moins profondément dégradée sous l'influença de ces médicaments.
On utilise généralement à cet effet des cultures déshy-
<Desc/Clms Page number 2>
drames ou lyophilisées de différents bacille lont un des rôles est; de permettre au milieu intestinal de secréser les vitamines - en particulier du groupe B - indispensable au ' notionnement équilibré de l'organisme,
Les nouveaux médicaments faisant l'o@ et de la pré- tante demande de Brevet Spécial de Médicament avnt caractérisés par le fait qu'ils comportent à côté des cultur vivantes con- venablement déshydratées des différents bacille que l'on dési- reréintroduire dans le milieu intestinal, une c@@@aine quantité de Sorbitol.
La présence de celui-ci exerce une infl j nce considé- rable en permettant une assimilation beaucoup plu rapide, dès leur formation, des vitamines que les bacillos nc'-. tellement in- trc@uits sécrètent,assurant par cela même un taux t'assimilation beaucoup plus important.
. Il est remarquable que l'action légèrement @actéric- statique du Sorbitol n'exerce aucune influence nocive sur le développement dos cultures une fois réintroduites dans lè milieu favorable.
Les bacilles susceptibles d'être utilisés sans inoon- vénients en présence' du Sorbitol doivent être de préférence vi- vants et originaires de souches antibiorésistantes. Parmi ceux qui sont susceptibles d'être utilisés avec les meilleurs résul- tats on peut citer :le Bacillus Subtilis, les Saccharomyces, bacillus lactis.bacillus aoidophilus,les streptocoques tels que les bacilles lactiques tels que sureptococcus lactis, streptocoo- cas thermophilus,ainsi que bacillum bulgaricus, escherichia coli
Les quantités de germes vivants pouvant être utilisés varient suivant les espèces utilisées de 1 million à 100 mil- liards ou même davantage, par unité de prise.
Il est toutefois à noter que les quantités correspondant à l'activité optima
EMI2.1
outé 8 motl sont;. généralement inférieures à. celles utilisées lors de l'emploi prouvât san.sSorbitol, du fait du meilleur taux d'assimilation des vita- ux xzacs,- ;u groupe B sécrétées par les bactéries.
<Desc/Clms Page number 3>
:La quantité de Sorbitol nécessaire peut aller jusqu'à 2,5 g par prise. Néanmoins, l'absorption de quantités trop im- portantes est susceptible de provoquer des phénomènes de diar- rhées. L'addition de 0,25 g de Sorbitol par prise évite toujours ce risque et est généralement suffisante pour permettre une as- similation quasi totale des vitamines sécrétées dans le milieu intestinal.
Les médicaments selon l'invention peuvent être réali- sés sous toutes les formes pharmaceutiques usuelles, c'est-à-dire gélules, ampoules buvables, préparation lyophylisées, ou même comprimés, en présence des excipients pharmaceutiquement accep- tables.
Pour illustrer la présente demande de Brevet Spécial de Médicament, des exemples de réalisation de médicaments selon l'invention sont donnés ci-dessous, sans toutefois que les pré- cisions apportées puissent être interprétées de façon restric- tive quand à la portée générale de l'invention, en particulier en ce qui concerne la nature des germes, le dosage et la poso- logie.
EXEMPLE 1 - Gelules
Culture lyophylisée de lactobacillus acidophilus antibiorésistant et vivant titrant au moins 1 milliard de germes
Sorbitol 0,25 g
Excipient QS pour une gélule
Posologie :2 à 4 gélules par jour ou davantage, EXEMPLE 2 -Ampoules buvables
Bacillus Subtilis antibiorésistant vivant 50 milliards de germas
Sorbitol 0,50 g
Excipient QS pour une ampoule buva- ble de '10 ml Posologie : 1 à 2 ampoules par jour ou davantage
<Desc/Clms Page number 4>
Les médicaments selon l'invention peuvent être admi- nistrés de toutes les façons classiques et être adjoints à des alimente, notamment pour un usage pédiatrique.
Un cas parti- @ culier de réalisation spécialement intéressant est la prépara- tion dont un exemple est donné ci-dessous où le Sorbitol est adjoint à un yoehourt enrichi en germes vivants.
EXEMPLE 3 - Yoghourt spécial
Yoghourt enrichi en bacillus bulgarious antibiorésistant vivant 100 g contenant au moins 100 millions de germes vivants
Sorbitol Os?5 g
Parfum QS
Posologie !1 à 2 par jour
Ce mode de réalisation des produits selon l'invention se prête particulièrement à l'aromatisation, notamment avec les extraits naturels de fruits.
<Desc / Clms Page number 1>
"New drug combinations intended for the reconstitution of the intestinal flora"
We know the importance of the reseeding of the intestinal flora after treatment with antibiotics, which is always more or less deeply degraded under the influence of these drugs.
Dehydrated cultures are generally used for this purpose.
<Desc / Clms Page number 2>
dramas or freeze-dried from different bacillus one of the roles is; to allow the intestinal environment to secrete the vitamins - in particular of the B group - essential for the balanced assessment of the body,
The new drugs forming the subject of the present application for a Special Medicines Patent have been characterized by the fact that they comprise, alongside living cultures, suitably dehydrated, of the various bacilli that one wishes to re-introduce into the intestinal environment, a large amount of Sorbitol.
The presence of this exerts a considerable influence by allowing a much faster assimilation, as soon as they are formed, of the vitamins than the bacilli nc'-. so many intrusions secrete, thereby assuring a much higher rate of assimilation.
. It is remarkable that the mildly acteric-static action of Sorbitol exerts no harmful influence on the development of the crops once reintroduced into the favorable environment.
The bacilli which can be used without inconvenience in the presence of sorbitol should preferably be live and originate from antibiotic resistant strains. Among those which are likely to be used with the best results, mention may be made of: Bacillus Subtilis, Saccharomyces, bacillus lactis, bacillus aoidophilus, streptococci such as lactic bacilli such as sureptococcus lactis, streptococcus thermophilus, as well as as bacillum bulgaricus, escherichia coli
The quantities of live germs which can be used vary according to the species used from 1 million to 100 billion or even more, per unit dose.
It should be noted, however, that the quantities corresponding to the optimum activity
EMI2.1
outé 8 motl are ;. generally less than. those used during employment proved san.sSorbitol, because of the better rate of assimilation of vitamins xzacs, -; u group B secreted by bacteria.
<Desc / Clms Page number 3>
: The amount of Sorbitol required can be up to 2.5 g per dose. Nevertheless, the absorption of too large quantities is liable to provoke the phenomena of diarrhea. The addition of 0.25 g of Sorbitol per dose always avoids this risk and is generally sufficient to allow almost complete absorption of the vitamins secreted in the intestinal environment.
The medicaments according to the invention can be produced in all the usual pharmaceutical forms, that is to say capsules, drinkable ampoules, lyophilized preparations, or even tablets, in the presence of pharmaceutically acceptable excipients.
To illustrate the present Special Medicines Patent application, exemplary embodiments of medicaments according to the invention are given below, without however the details provided being able to be interpreted restrictively as regards the general scope of the invention. The invention, in particular with regard to the nature of the seeds, the dosage and the dosage.
EXAMPLE 1 - Gelatin capsules
Lyophilized culture of live, antibiotic-resistant lactobacillus acidophilus containing at least 1 billion germs
Sorbitol 0.25 g
Excipient QS for one capsule
Dosage: 2 to 4 capsules per day or more, EXAMPLE 2 - Drinkable ampoules
Antibiotic-resistant Bacillus Subtilis living 50 billion germs
Sorbitol 0.50 g
Excipient QS for a drinkable ampoule of '10 ml Dosage: 1 to 2 ampoules per day or more
<Desc / Clms Page number 4>
The medicaments according to the invention can be administered in all conventional ways and be added to foods, in particular for pediatric use.
A particularly interesting particular embodiment is the preparation, an example of which is given below, in which Sorbitol is added to a yoghurt enriched with living germs.
EXAMPLE 3 - Special yoghurt
Yogurt enriched with live antibiotic-resistant bacillus bulgarious 100 g containing at least 100 million live germs
Sorbitol Bone? 5 g
QS fragrance
Dosage! 1 to 2 per day
This embodiment of the products according to the invention is particularly suitable for flavoring, in particular with natural fruit extracts.
Claims (1)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR957048A FR3233M (en) | 1963-12-13 | 1963-12-13 | New drug combinations intended for the reconstitution of the intestinal flora. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE657005A true BE657005A (en) | 1965-04-01 |
Family
ID=8818760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE657005A BE657005A (en) | 1963-12-13 | 1964-12-11 |
Country Status (3)
| Country | Link |
|---|---|
| BE (1) | BE657005A (en) |
| FR (1) | FR3233M (en) |
| NL (1) | NL6414479A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4335107A (en) * | 1978-06-05 | 1982-06-15 | Snoeyenbos Glenn H | Mixture to protect poultry from salmonella |
-
1963
- 1963-12-13 FR FR957048A patent/FR3233M/en not_active Expired
-
1964
- 1964-12-11 BE BE657005A patent/BE657005A/fr unknown
- 1964-12-11 NL NL6414479A patent/NL6414479A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NL6414479A (en) | 1965-06-14 |
| FR3233M (en) | 1965-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60003515T2 (en) | BEVERAGES AND FOODS SUITED TO ELIMINATE HELICOBACTER PYLORI | |
| US11160753B2 (en) | Transmucosal and transdermal delivery systems | |
| EP2219658B1 (en) | Composition based on probiotic bacteria in association with a prebiotic and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of intestinal functionality | |
| Bharath et al. | Determination of antibacterial activity of green coffee bean extract on periodontogenic bacteria like Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans: An: in vitro: study | |
| AU2018281141B2 (en) | Compositions for management of Helicobacter pylori infections | |
| KR102606636B1 (en) | Bacillus velezensis having the effect of preventing or improving for sarcopenia and uses thereof | |
| JPH0138084B2 (en) | ||
| US9717751B2 (en) | Chitin or derivatives thereof for the prevention and/or treatment of parasitoses | |
| KR20210112342A (en) | Strain, composition and method of use | |
| HUP0402024A2 (en) | Solid composition containing bacillus-type non-pathogenic bacterial spores | |
| JP3017493B1 (en) | Autoimmune disease prevention composition | |
| KR20240152811A (en) | Composition for antibacterial and toxicity inhibition against antibiotic-resistant bacteria containing black ginseng extract as an active ingredient | |
| WO1996026732A1 (en) | Compositions of lactic acid bacteria and saccharomyces lysates and the therapeutical use thereof | |
| JP7009396B2 (en) | MRSA infection protection agent | |
| JPH0217524B2 (en) | ||
| BE657005A (en) | ||
| KR20220079092A (en) | Composition for preventing or treating inflammatory diseases containing new strains | |
| US10695314B2 (en) | Antimicrobial composition containing 7,10-epoxyoctadeca-7,9-dienoic acid as active ingredient | |
| RU2472505C2 (en) | Therapeutic antimalaria drug based on antimalaria agent and probiotic | |
| US20030109582A1 (en) | Methods and compositions for stimulating secretions from paneth cells | |
| KR102847918B1 (en) | Anti-inflammatory and anti-bacterial efficacy microorganism and microorganism lysates fermented in media containing Filipendula glaberrima Nakai extracts | |
| CN117224582A (en) | Application of lactobacillus plantarum in preparation of product for preventing and/or treating acne | |
| KR20200112804A (en) | Pharmaceutical compositions for preventing or treating the acquisition of drug resistant infections comprising a combination of probiotics and prebiotics | |
| KR100319365B1 (en) | Medicinal herbs extract for preventing and treating gastric ulcers and the use thereof | |
| RU2149008C1 (en) | Method of biopreparation preparing |